Скачать с ютуб What’s New In Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma в хорошем качестве

What’s New In Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is characterized by the accumulation of CD19+CD5+ cells in bone marrow, lymph nodes, spleen, and peripheral blood. Although the 5-year relative survival is high and CLL/SLL mortality accounts for only about 1% of all cancer deaths, survival statistics are lower in patients with relapsed/refractory (R/R) CLL/SLL who represent a particularly difficult-to-treat patient population. Fortunately, the approval of new lines of therapy, such as pirtobrutinib and the chimeric antigen receptor (CAR) T-cell therapy, lisocabtagene maraleucel (liso-cel), have yielded promising results for the treatment of R/R CLL/SLL. In this program, Dr. Ann LaCasce reviews the latest and most pivotal clinical data on the management of CLL/SLL, as well as how best to apply these recent findings in clinical practice. View this program in its entirety https://exchangecme.com/groups/2024NH... Clinical Resources in NHL https://exchangecme.com/NHLConference... ExchangeCME.com is an online community of more than 57,000 active healthcare professionals who have access to a variety of enduring educational activities and other disease state–focused resources. The Website’s core mission is to support patient-centered care via education that is tailored to the needs of various clinician audiences. By consolidating evidence-based resources and hosting only accredited educational programs without any promotional content or advertising, ExchangeCME.com serves as an independent, trusted, and balanced source of free CME/CE for physicians, nurses, pharmacists, and other healthcare providers. Follow us on social! twitter:   / exchangecme   facebook:   / exchangecme   linkedin:   / exch.  .